Prostate cancer
Conditions
Interventions
Observation group:None
Sponsors
Lishui Central Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Received radical prostatectomy (RP) at this hospital between 2021-2024 and completed a complete mpMRI examination before surgery (must include T2WI and ADC sequences); 2. Postoperative pathology report complete, including pT stage, ISUP grade, margin status, and lymph node metastasis status; 3. At least 2 years of regular PSA follow-up (every 3-6 months), able to clearly identify biochemical recurrence (BCR) events (defined as two consecutive postoperative PSA levels =0.2 ng/mL, with the recurrence date being the date the first PSA value >0.20 ng/mL was recorded;for patients without BCR, BCRFS is calculated from the RP date to the date BCR was confirmed or the most recent follow-up date); 4.Complete clinical information (age, preoperative PSA, postoperative PSA at 6 weeks, volume, BMI, etc.), postoperative follow-up information (every 3 months for the first 2 years, every 6 months for the third and fourth years, and annually thereafter, with PSA measured at each follow-up).
Exclusion criteria
Exclusion criteria: 1. Has received any form of prostate cancer-related treatment before surgery (hormonal, radiation, chemotherapy); 2.MRI image quality does not meet the standard (severe motion artifacts, missing sequences, or insufficient resolution); 3. Pathology report missing or ISUP grade cannot be confirmed; 4. Patients lost to follow-up, missing key PSA data, or with unclear time of death.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate-specific antigen;Discriminability;Clinical practicality; | — |
Countries
China
Contacts
Public ContactJiafeng Ding
Lishui Central Hospital
Outcome results
None listed